HRTX
HERON THERAPEUTICS, INC. /DE/
NASDAQ · Healthcare · Biotechnology · US
$0.30
+4.88%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.29
From 52W high−79.96%
Volume968983.00
Market cap$56.69M
P/E (TTM)—
P/S (TTM)0.4x
Div yield—
Key dataNov 4, 2026
Open
$0.29
From 52W high
−79.96%
Volume
968983.00
Market cap
$56.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.8x
P/E (TTM)
—
RSI (14)
42.7
MomentumView details →
1D Return
+4.88%
YTD Return
−77.41%
SummaryUpdated Jun 1, 2026
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a San Diego-based biotechnology company founded in 1983 that develops specialized treatments for unmet medical needs in oncology and acute care settings. Originally known as A.P. Pharma, Inc., the company rebranded to Heron Therapeutics in 2014 to reflect its focus on innovative drug delivery technologies. The company has evolved from a development-stage biotechnology firm to a commercial-stage pharmaceutical company with multiple approved products generating over $144 million in annual revenue as of 2024.
Similar companies
Latest newsMore news →
Heron Therapeutics, Inc. signed a Development and License Agreement granting it an exclusive license to import, distribute, sell and market certain products in the United States and a non-exclusive worldwide manufacturing license, with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC as counterparties.36d agoHeron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.87d ago